Citadel Advisors
TARS icon

Citadel Advisors’s Tarsus Pharmaceuticals TARS Stock Holding History

Citadel Advisors’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.37M Buy
21,700
+5,800
+36% +$371K ﹤0.01% 7437
2026
Q1 		$1.12M Buy
+15,900
New +$1.11M ﹤0.01% 7428
2025
Q4 		– Sell
-6,600
Closed -$392K – 14044
2025
Q3 		$392K Sell
6,600
-1,200
-15% -$59.1K ﹤0.01% 9712
2025
Q2 		$316K Sell
7,800
-6,800
-47% -$306K ﹤0.01% 9695
2025
Q1 		$750K Buy
14,600
+2,200
+18% +$109K ﹤0.01% 7594
2024
Q4 		$687K Sell
12,400
-2,400
-16% -$109K ﹤0.01% 7873
2024
Q3 		$487K Buy
14,800
+7,900
+114% +$222K ﹤0.01% 8313
2024
Q2 		$188K Sell
6,900
-5,200
-43% -$175K ﹤0.01% 10035
2024
Q1 		$440K Sell
12,100
-600
-5% -$17.6K ﹤0.01% 8672
2023
Q4 		$257K Buy
12,700
+800
+7% +$13.4K ﹤0.01% 9470
2023
Q3 		$211K Buy
11,900
+9,200
+341% +$163K ﹤0.01% 9794
2023
Q2 		$48.8K Buy
2,700
+2,200
+440% +$35K ﹤0.01% 11830
2023
Q1 		$6.29K Sell
500
-38,900
-99% -$569K ﹤0.01% 13819
2022
Q4 		$578K Buy
39,400
+500
+1% +$8.27K ﹤0.01% 7942
2022
Q3 		$666K Buy
38,900
+1,400
+4% +$22.2K ﹤0.01% 7852
2022
Q2 		$548K Buy
+37,500
New +$563K ﹤0.01% 8442

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors's TARS Position: Q2 2026 in Review

Citadel Advisors increased its Tarsus Pharmaceuticals (TARS) stake by 47% in Q2 2026, buying an estimated $4.97M and bringing the position to 241,737 shares worth $15.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2941.

Citadel Advisors first reported a position in TARS in Q1 2022 and has held it in 16 quarters since. The position peaked at $51M in Q1 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Citadel Advisors held 241,737 shares of Tarsus Pharmaceuticals worth $15.2M as of Q2 2026.
  • Citadel Advisors bought 77,740 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $4.97M.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2941 holding.
  • Citadel Advisors first reported a position in Tarsus Pharmaceuticals in Q1 2022 and has held it in 16 quarters since.
  • Citadel Advisors's Tarsus Pharmaceuticals position peaked at $51M in Q1 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.